BOOK
Type 1 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America, E-Book
Desmond A. Schatz | Michael Haller | Mark Atkinson
(2010)
Additional Information
Book Details
Abstract
This issue of Endocrinology and Metabolism Clinics of North America provides the endocrinologist with essential updates on treatment of type 1 diabetes, with an eye toward future trends and developments. The Guest Editors brought together a remarkable group of notable authors, such as Paul Robertson, President of the National Diabetes Association. Topics covered include epidemiology; economics; contemporary management; inpatient management; update on insulin pumps and continuous glucose monitoring systems; update on studies aimed at interdicting and preventing type 1 diabetes; advances in the prediction, natural history, and mechanisms leading to type 1 diabetes; complications; hypoglycemia in type 1 diabetes; new lessons from animal models; the role of the gut in the genesis of type 1 diabetes and other autoimmune diseases; and an update on transplantation for reversing type 1 diabetes.
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | Cover | ||
Contributors | iii | ||
Contents | vii | ||
Foreword | xiii | ||
Preface | xvii | ||
Chapter 1. Epidemiology of Type 1 Diabetes | 481 | ||
INCIDENCE AND PREVALENCE OF T1D | 482 | ||
INCIDENCE: TEMPORAL TRENDS | 483 | ||
RISK FACTORS FOR DEVELOPMENT OF T1D | 484 | ||
SEASONALITY OF ONSET AND BIRTH | 486 | ||
OTHER RISK FACTORS | 487 | ||
CLINICAL COURSE | 488 | ||
TREATMENT AND MANAGEMENT | 488 | ||
PREVALENCE OF COMPLICATIONS | 489 | ||
SUMMARY | 490 | ||
REFERENCES | 491 | ||
Chapter 2. Economics of Type 1 Diabetes | 499 | ||
COST OF ILLNESS: METHODS AND DATA | 500 | ||
T1D COSTS | 504 | ||
SUMMARY | 509 | ||
REFERENCES | 510 | ||
Chapter 3. Advances in the Prediction and Natural History of Type 1 Diabetes | 513 | ||
GENETIC MARKERS OF T1D RISK | 514 | ||
ISLET AUTOANTIBODIES: FORENSIC PREDICTION | 516 | ||
NATURAL HISTORY OF ISLET AUTOIMMUNITY | 519 | ||
SPECULATIONS FROM THE NATURAL HISTORY FINDINGS | 520 | ||
SUMMARY | 521 | ||
ACKNOWLEDGMENTS | 522 | ||
REFERENCES | 522 | ||
Chapter 4. Efforts to Prevent and Halt Autoimmune Beta Cell Destruction | 527 | ||
PREVENTION VERSUS INTERVENTION | 527 | ||
PREVENTION STRATEGIES | 529 | ||
INTERVENTION STRATEGIES | 530 | ||
SUMMARY | 536 | ||
REFERENCES | 536 | ||
Chapter 5. Use of Nonobese Diabetic Mice to Understand Human Type 1 Diabetes | 541 | ||
IMMUNOLOGY AND PATHOLOGY OF T1D: COMPARING MICE AND MEN | 543 | ||
GENETICS | 548 | ||
PRECLINICAL TRIALS | 552 | ||
SUMMARY | 553 | ||
REFERENCES | 553 | ||
Chapter 6. The Intestinal Microbiome: Relationship to Type 1 Diabetes | 563 | ||
THE HUMAN SUPERORGANISM | 564 | ||
INTESTINAL MUCOSAL IMMUNOLOGY IN RELATION TO T1D | 565 | ||
ALTERED INTESTINAL MICROBIOTA IN T1D | 566 | ||
INTESTINAL MUCOSAL BARRIER—MICROBIAL INTERACTION | 566 | ||
PROBIOTICS AND T1D | 568 | ||
MICROBIAL INTERACTION WITH NUTRIENTS, IMMUNITY AND PATHOGENESIS OF T1D | 568 | ||
SUMMARY | 569 | ||
REFERENCES | 569 | ||
Chapter 7. Contemporary Management of Patients with Type 1 Diabetes | 573 | ||
HISTORICAL BACKGROUND | 573 | ||
MULTIDISCIPLINARY DIABETES TEAM | 574 | ||
INSULIN ANALOGUES | 574 | ||
INSULIN REGIMENS | 582 | ||
INSULIN PUMP THERAPY | 583 | ||
MEDICAL NUTRITION THERAPY | 585 | ||
BLOOD GLUCOSE MONITORING | 586 | ||
SUMMARY | 587 | ||
REFERENCES | 587 | ||
Chapter 8. Inpatient Management of Adults and Children with Type 1 Diabetes | 595 | ||
INSULIN PHARMACOKINETICS AND PHARMACODYNAMICS | 596 | ||
FUNDAMENTALS OF INSULIN MANAGEMENT | 597 | ||
METHODS OF SUBCUTANEOUS INSULIN ADMINISTRATION | 598 | ||
INPATIENT GLYCEMIC GOALS | 599 | ||
INSULIN SELF-MANAGEMENT | 601 | ||
ADJUSTING THE INPATIENT REGIMEN | 601 | ||
ADJUSTING SUBCUTANEOUS INSULIN | 602 | ||
TPN, TUBE FEEDING, AND GLUCOCORTICOIDS | 602 | ||
INTRAVENOUS INSULIN | 603 | ||
PERIOPERATIVE INSULIN | 604 | ||
TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INSULIN | 604 | ||
WRITING ORDERS | 605 | ||
ADDITIONAL CONSIDERATIONS FOR CHILDREN | 606 | ||
DISCHARGE PLANNING | 606 | ||
SUMMARY | 606 | ||
REFERENCES | 606 | ||
Chapter 9. Toward Closing the Loop: An Update on Insulin Pumps and Continuous Glucose Monitoring Systems | 609 | ||
SENSORS | 611 | ||
CLINICAL POINTERS IN THE USE OF CGM SENSORS TODAY | 613 | ||
PUMPS | 615 | ||
INFUSION SETS | 617 | ||
INSULIN | 617 | ||
ALGORITHMS | 617 | ||
POTENTIAL FUTURE APPLICATIONS OF A CLOSED-LOOP SYSTEM | 619 | ||
SUMMARY | 619 | ||
REFERENCES | 620 | ||
Chapter 10. Complications of Type 1 Diabetes | 625 | ||
BIOCHEMICAL AND MOLECULAR PATHWAYS OF DAMAGE | 626 | ||
METABOLIC MEMORY | 627 | ||
MICROVASCULAR COMPLICATIONS | 628 | ||
MACROVASCULAR COMPLICATIONS | 636 | ||
REFERENCES | 637 | ||
Chapter 11. Hypoglycemia in Type 1 Diabetes Mellitus | 641 | ||
THE LIMITING FACTOR IN GLYCEMIC CONTROL | 641 | ||
INCIDENCE AND IMPACTS OF HYPOGLYCEMIA IN T1DM | 642 | ||
DEFINITION OF HYPOGLYCEMIA IN T1DM | 642 | ||
PHYSIOLOGY OF GLUCOSE COUNTER-REGULATION | 643 | ||
PATHOPHYSIOLOGY OF GLUCOSE COUNTER-REGULATION IN T1DM | 643 | ||
RISK FACTORS FOR HYPOGLYCEMIA IN T1DM | 646 | ||
MINIMIZING THE RISK OF HYPOGLYCEMIA IN T1DM | 646 | ||
TREATMENT OF HYPOGLYCEMIA IN T1DM | 649 | ||
SUMMARY OF RECOMMENDATIONS | 650 | ||
ACKNOWLEDGMENTS | 650 | ||
REFERENCES | 651 | ||
Chapter 12. Update on Transplanting Beta Cells for Reversing Type 1 Diabetes | 655 | ||
HISTORY OF PANCREAS AND ISLET TRANSPLANTATION | 655 | ||
GRAFT SURVIVAL RATES | 656 | ||
PATIENT SURVIVAL RATES AND COMPLICATIONS OF TRANSPLANTATION | 657 | ||
PANCREAS AND ISLET CELL FUNCTION POST TRANSPLANT | 658 | ||
IMPACT ON SECONDARY COMPLICATIONS OF DIABETES | 661 | ||
PROBLEMS WITH IMMUNOSUPPRESSIVE DRUGS | 663 | ||
PROBLEMS WITH TRANSPLANTATION SITES | 664 | ||
PROBLEMS WITH SUPPLY AND DEMAND | 664 | ||
SUMMARY | 665 | ||
REFERENCES | 665 | ||
Index | 669 |